GlassScriptPhysician profile
Amol Rakkar
NPI 1336160241
$17,670.46
in general payments reported to CMS, 2019-2025
82 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $2,032 · 2021: $736 · 2022: $1,956 · 2023: $4,928 · 2024: $3,290 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,546 · Consulting Fee: $2,299 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,545.62 |
| Consulting Fee | $2,299.00 |
| Education | $151.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,336.64 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $1,563.47 | 2020-2023 | Adcetris, Tukysa |
| Mirati Therapeutics, INC. | $1,013.68 | 2023-2024 | Krazati |
| Pfizer INC. | $962.03 | 2019-2025 | |
| Daiichi Sankyo INC. | $823.93 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $734.41 | 2019-2025 | |
| Celgene Corporation | $722.65 | 2022-2025 | Reblozyl, Pomalyst |
| Emd Serono, INC. | $666.49 | 2019-2025 | |
| Janssen Biotech, INC. | $638.58 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $593.03 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $515.94 | 2019-2025 | Tecentriq, Polivy, Perjeta |
| Spectrum Pharmaceuticals INC. | $500.00 | 2023 | |
| Amgen INC. | $473.16 | 2019-2024 | Vectibix, Nplate, Kyprolis |
| Incyte Corporation | $449.72 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $413.14 | 2019-2025 | Enhertu, Imfinzi |
Show all 78 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amol Rakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.